Alternative genetic pathways were previously outlined in the pathogenesis of therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) based on cytogenetic characteristics. Some of the chromosome aberrations, the recurrent balanced translocations or inversions, directly result in chimeric rearrangement of genes for hematopoietic transcription factors (class II mutations) which disturb cellular differentiation. Other genetic abnormalities in t-MDS and t-AML comprise activating point mutations or internal tandem duplications of genes involved in signal transduction as tyrosine kinase receptors or genes more downstream in the RAS-BRAF pathway (class I mutations). The alternative genetic pathways of t-MDS and t-AML can now be further characterized by a different clustering of six individual class I mutations and mutations of AML1 and p53 in the various pathways. In addition, there is a significant association between class I and class II mutations possibly indicating cooperation in leukemogenesis, and between mutations of AML1 and RAS related to subsequent progression from t-MDS to t-AML. Therapy-related and de novo myelodysplasia and acute myeloid leukemia seem to share genetic pathways, and surprisingly gene mutations were in general not more frequent in patients with t-MDS or t-AML as compared to similar cases of de novo MDS and AML studied previously.
Introduction
Identification of cytogenetic abnormalities is essential for prognostic evaluation and for choice of therapy in MDS and AML. [1] [2] [3] [4] In the therapy-related subsets of these diseases mainly observed after cancer chemotherapy, the cytogenetic abnormalities in addition reflect the etiology of the disease. Thus, patients treated with alkylating agents are primarily at risk of developing t-MDS with deletion or loss of the long arm or total loss of chromosome 5 (5qÀ/À5) and/or deletion or loss of the long arm or total loss of chromosome 7 (7qÀ/À7). Patients treated with topoisomerase II inhibitors, on the other hand, are at risk of developing overt t-AML with one of the several recurrent balanced chromosome aberrations. [5] [6] [7] Most cases of de novo AML present without knowledge of a preleukemic phase of MDS. In t-AML, however, when such a phase is present, it is rarely overlooked, because patients after radiotherapy or chemotherapy for other cancers are followed with blood tests and clinical evaluation for relapse of the primary tumor and for development of complications. This makes t-MDS and t-AML an ideal model for studies of progression from MDS to AML.
Based on cytogenetic characteristics we previously proposed eight different genetic pathways of t-MDS and t-AML. 5, 8 Since then, no new important class of chromosome abnormality has been observed. However, many studies primarily of patients with de novo MDS and AML have reported on other genetic changes such as point mutations, internal tandem duplications (ITD) and duplication or amplification of genes of importance for hematopoiesis. A cooperation between so-called class I mutations of genes encoding tyrosine kinase receptors or of genes more downstream in the RAS-BRAF pathway, and class II mutations of genes for putative hematopoietic transcription factors has been proposed. 9, 10 These observations and the results of our investigation of the same 140 unselected patients with t-MDS or t-AML and bone marrow material available for mutations of the FLT3, cKIT, PTPN11, NRAS, KRAS, BRAF, c-FMS, JAK2, CEBPA, p53 and AML1 genes, [11] [12] [13] [14] [15] [16] support the existence of alternative genetic pathways of the disease, as outlined in the following revised model for leukemic transformation.
Revised model

Pathway I
This pathway includes patients with t-MDS or t-AML and 7qÀ/ À7 but normal chromosomes 5 and without any of the recurrent balanced chromosome aberrations. The disease is closely associated with previous therapy with alkylating agents and with presentation as t-MDS (Figure 1 ). In our series of 140 patients with t-MDS or t-AML examined for class I mutations, 35 of 39 patients in this pathway had received alkylating agents, and 35 of 39 patients presented as t-MDS. Methylation of the p15 promotor was previously shown as a common phenomenon particularly in cases with abnormalities of chromosome 7. 17 The methylation demonstrated to increase by leukemic progression from refractory anemia to refractory anemia with excess of blasts in transformation, was considered a late event in leukemogenesis.
Subsequent studies have shown that point mutation of the AML1 or RUNX1 gene is a common abnormality in t-MDS, 13, 18 and we observed a highly significant clustering of this abnormality in pathway I. 13 Thus, 38% of the patients in this pathway (15 cases) had AML1 mutations (Figure 1 ). Besides a close association to 7qÀ/À7, AML1 mutations were significantly associated with presentation of the disease as t-MDS and with subsequent progression to overt t-AML. Among the 39 patients in pathway I a smaller subgroup of five cases presented p53 mutations and another subgroup of only 3 cases presented RAS mutations. Four of the five patients with p53 mutations and two of the three cases with RAS mutations also had AML1 point mutations suggesting a cooperation in leukemogenesis. Mutations of FLT3 were not observed in patients in pathway I.
Pathway II
Patients with the chromosomal defects 5qÀ/À5 but without any of the recurrent balanced aberrations belong to this pathway. Some cases in addition have the 7qÀ/À7 deletions or loss characteristic of pathway I. Also in pathway II the disease is closely associated with previous therapy with alkylating agents and presentation as t-MDS (Figure 1 ). In our series, 27 out of 34 patients in pathway II had received alkylating agents, and 26 of 34 patients presented as t-MDS. In a previous study, we have shown that mutations of p53 are highly characteristic of this pathway. 11 The close association between 5qÀ/À5 and mutation of p53 is confirmed by our so far unpublished follow-up study showing that in total 25 of the 34 patients in pathway II (77%) presented a p53 mutation (Po0.0001). Deletion or loss of 17p resulting in loss of heterozygosity of p53, 11 complex karyotypes, 11 chromosome derivatives composed of material from at least three different chromosomes 19 and amplification or duplication of chromosome bands 11q23 20 and 21q22 21 are all characteristic of pathway II (Figure 1 ). In pathway II mutation of the RAS or the FLT3 gene was observed in only a single patient each, and only three patients presented AML1 point mutations including two cases with an additional 7qÀ/À7.
A separation between pathways I and II is further supported by different gene expression profiles of CD34 positive bone marrow cells of patients in the two pathways. 22, 23 Pathway III This pathway is characterized by balanced translocations to chromosome band 11q23 (Figure 1 ) with chimeric rearrangement between the MLL gene and one of its many partner genes. This is the most common abnormality of t-AML after therapy with topoisomerase II inhibitors, particularly after epipodophyllotoxins [24] [25] [26] [27] In our series, eight out of 11 patients in pathway III had received topoisomerase II inhibitors, and all 11 patients presented as overt t-AML of FAB subtypes M4 or M5. In pathway III, three out of 11 patients had a RAS mutation, and another three patients a BRAF mutation 14 ( Figures 1 and 2 ). RAS mutations have also in AML de novo been associated with FAB subtypes M4 or M5 and with balanced translocations to chromosome band 11q23.
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Figure 1 Genetic pathways of t-MDS and t-AML; 140 cases studied (c) denotes significant association with transformations from t-MDS to t-AML.
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Pathway IV
Patients with balanced translocations involving chromosome band 21q22 or 16q22 leading to chimeric rearrangements between the core binding factor genes AML1 or CBFB and their various partner genes are grouped together in this pathway ( Figure 1 ). Also these abnormalities have been associated with previous therapy with topoisomerase II inhibitors, most often anthracyclines. [31] [32] [33] Seven of our 10 patients in this pathway had received topoisomerase II inhibitors. Whereas patients with t(3;21)(q26;q22) and rearrangement between the EVI1 and AML1 genes often present as t-MDS, most other patients belonging to pathway IV present as overt t-AML ( Figure 1 ). Interestingly, 7qÀ/ À7 was in the International Workshop Study of t-MDS and t-AML the most common secondary cytogenetic abnormality in patients with balanced translocations to chromosome band 21q22. 33 We have observed defects of chromosme 7 in five of nine patients with translocations to 21q22 and rearranged AML1. Thus, abnormalities of AML1 of two types, point mutations as observed in pathway I, and chimeric gene fusions as observed in pathway IV, are both associated with defects of chromosome arm 7q. Mutations of the c-KIT gene, have in de novo AML been shown to cluster in patients with rearrangement of the core binding factor genes. [34] [35] [36] One of our only two patients with c-Kit mutations and two of our only four patients with PTPN11 mutations belong to pathway IV 14,15 ( Figure 2 ).
Pathway V
Balanced translocations involving chromosome band 17q12, most often t(15;17)(q22;q12-21), with chimeric rearrangement between the PML and the RARA gene, define this pathway ( Figure 1 ). Therapy-related promyelocytic leukemia is reported increasingly these years particularly in patients treated with doxorubicin or mitoxantrone for breast cancer. [37] [38] [39] Most patients in this pathway present with overt t-AML, and like their counterpart of patients with de novo AML and t(15;17) they often respond favorably to therapy with retinoic acid. One of our only two patients in this pathway presented an FLT3 internal tandem duplication (Figure 2 ). This is in agreement with the experience from de novo AML in which FLT3 mutations have been shown to cluster in cases with t(15;17) and in cases with a normal karyotype. [40] [41] [42] In pathways III-V including in total 23 patients, a p53 mutation was observed in only a single case (no 178), and point mutations of AML1 were not observed. The unique case 178 with t(9;11) and p53 mutation also had two different FLT3 mutations, one ITD and one D835 point mutation.
Pathway VI
This pathway includes rather rare patients with t-MDS or t-AML and balanced translocations to chromosome band 11p15 and rearrangement of the NUP98 gene with one of its many partner genes. [43] [44] [45] [46] [47] We have not so far observed such cases. To our knowledge, no type II mutation has so far been shown to cluster in patients in this pathway.
Pathway VII
Patients with a normal karyotype belong to pathway VII. Such cases most often present as overt t-AML (Figure 1) , and 17% of our 140 patients are grouped in this pathway. In de novo MDS and AML a much larger subgroup of about 50% of the patients present a normal karyotype. [1] [2] [3] [4] As in de novo MDS and AML more recent techniques such as multicolour FISH have not in t-MDS and t-AML with a normal karyotype been able to detect chromosome abnormalities overlooked by conventional Gbanding. 19 A normal karyotype is often observed in atypical cases of t-MDS and t-AML and has not been associated with any specific type of previous therapy. Such patients have been suggested often to represent sporadic cases of de AML occurring among the many therapy-induced cases.
Patients belonging to pathway VII, like patients with de novo AML and a normal karyotype, rather frequently have mutations of FLT3 or RAS, 30, [40] [41] [42] and AML1 mutations are also observed, although less frequently. 18, 48 Among our 24 patients with a normal karyotype 50% had a mutation of at least one of these three genes 13, 14 as six patients showed FLT3 mutations, all internal tandem duplications, five patients had RAS mutations and three patients AML1 mutations. The AML1 mutations were in two of three cases combined with a RAS mutation. Only a single case with a p53 mutation was observed in pathway VII.
A point mutation of the JAK2 gene has been detected with a high frequency in patients with myeloproliferative diseases as polycythemia vera (77%), idiopatic myelofibrosis (48%) and essential thrombocythemia (35%). 49, 50 The same mutation has subsequently been observed sporadically in patients with de novo MDS and a normal karyotype 51 and in rare atypical cases of t-MDS with splenomegalia and normal cytogenetics. 16 Such patients should perhaps be reclassified as myeloproliferative diseases rather than t-MDS.
Mutations of the NPM1 gene have recently been demonstrated to be the most frequent genetic abnormality in patients with de novo AML and a normal karyotype. 52, 53 The mutations were significantly associated with FLT3 internal tandem duplications suggesting cooperation in leukemogenesis. Patients with NPM1 mutations but without FLT3 internal tandem duplications had a more favorable prognosis. So far patients with t-MDS and t-AML have not been examined for NPM1 mutations.
Interestingly, only 50% of our patients in pathway VII showed methylation of the p15 promotor 17 despite the fact that a major part presented as overt t-AML. Internal tandem duplications of the MLL gene have also been observed to cluster in this pathway 20 similarly to the experience from AML de novo with a normal karyotype. 54, 55 Pathway VIII Uncharacteristic, sometimes unique chromosome aberrations are grouped together in this pathway comprising 14% of our cases of t-MDS or t-AML. Like in pathway VII their disease is not related to any specific type of previous therapy, and clinical data support that many cases could represent cases of de novo MDS and AML. Patients in pathway VIII often present as t-MDS and methylation of the p15 promotor is less common. 13 The mutations of genes in the RTK/RAS-BRAF pathway, of p53 and of AML1 observed in the other pathways were in our series uncommon in pathway VIII except for two of 20 patients presenting RAS mutations. 14 
Origin of chromosome aberrations and specific mutations in t-MDS and t-AML
As alkylating agents, topoisomerase II inhibitors and X-rays experimentally have been shown to be mutagenic and to induce chromosome damage, the cytogenetic abnormalities and the gene mutations observed in t-MDS and t-AML could be direct consequences of previous therapy. However, it is surprising, that gene mutations in general were not more frequently observed in our series of t-MDS and t-AML as compared to similar cases of de novo MDS and AML studied previously. Until now, most studies have been devoted to clarify the mechanisms leading to development of the balanced chromosome translocations of pathways III-VI. 56 The recurrent, reciprocal translocations and the inv(16) in these pathways result in rearrangement of genes often encoding putative hematopoietic transcription factors with formation of new chimeric, dominant oncogenes. The enzyme topoisomerase II induces double-strand breaks of DNA to relax supercoiling. Cytostatic agents belonging to the topoisomerase II inhibitors interfere with rejoining of these double-strand breaks, and this activity is believed in some way to increase the risk of two simultaneous, illegitimate recombinations between the broken DNA strands of adjacent chromosomes. Studies of the genomic break-points of cases belonging to pathways III-VI now support this hypothesis, 39, [57] [58] [59] [60] [61] as the break points colocalize with topoisomerase II breakage sites.
As far as the unbalanced chromosome aberrations are concerned, their development as a direct consequence of exposure to alkylating agents is more uncertain. A clustering of break points at the centromeric or percentric region of several chromosomes including no 5 and no 7 was recently observed in t-MDS and t-AML after therapy with alkylating agents. 19 This suggests that the centromeric or pericentric region devoid of genes could be particularly prone to breakage following alkylation. If not rejoined homogeneously or by the formation of a dicentric chromosome, centromeric breakage will result in a loss of the two chromosome fragments at a subsequent cell division. By such a mechanism hypodiploidy with loss of chromosomes 5 and 7 could be a direct result of exposure to alkylating agents.
The significant associations between point mutations of the AML1 gene in pathway I and of the p53 gene in pathway II and previous therapy with alkylating agents suggest that also these mutations could be directly drug induced. In our series, 19 of 22 patients with AML1 mutations and 26 of 34 patients with p53 mutations had received alkylating agents. As far as the FLT3 and the RAS mutations are concerned, our results support that these abnormalities often arise unrelated to chemotherapy, sometimes related to previous radiotherapy, in other cases by so far unknown mechanisms. 14 The internal tandem duplications of FLT3 and of MLL have been suggested to reflect a common category of genomic stress. 62 This is possible, but we could not confirm the suggested relation to previous therapy with topoisomerase II inhibitors.
Cooperating genetic abnormalities in t-MDS and t-AML
A cooperation between two types of mutation, class I mutations of genes involved in signal transduction and class II mutations of Figure 2 Cooperating genetic abnormalities in t-MDS and t-AML; 140 cases studied. 33/140 patients presented a class I mutation and 47/140 patients presented a class II mutation. In total 18 patients presented both types of mutation (w 2 ¼ 7.33, P ¼ 0.007). Two of 10 patients with AML1 or CBFB chimeric rearranged are also included in the subgroup of four patients with rearranged EVI1. *Denotes one patient (case 66) presented a KRAS as well as a BRAF mutation; 1three of these five patients presented normal chromosomes 7; D four of these five patients presented normal chromosomes 5; w only two of these 34 patients presented class I mutations (of cKit in case 126 and of FLT3 in case 178).
Alternative genetic pathways in therapy-related MDS/AML J Pedersen-Bjergaard et al genes encoding hematopoietic transcription factors such as AML1, CBFB, RARA and MLL was recently proposed in AML. 9, 10 Our results in 140 patients with t-MDS or t-AML now strongly support this hypothesis. Among 33 patients with class I mutations and 47 patients with class II mutations 18 cases presented both types of mutation ( Figure 2 , w 2 ¼ 7.33, P ¼ 0.007 for an association). Whereas 15 of 47 patients in pathways III-V or VII presented a combination of class I and class II mutations, this was only observed in three of 73 patients in pathways I and II. As shown in Figure 2 there were characteristic associations between chimeric rearrangement of the MLL gene and RAS and BRAF mutations, and between AML1 point mutations and RAS mutations. Interestingly, three of our four patients with PTPN11 mutations had the defects 7qÀ/À7, and all four had rare balanced translocations, in two patients to chromosome band 21q22 with rearrangement of the AML1 gene and in other two patients to chromosome band 3q26 with rearrangement of the EVI1 gene. 15 Also in de novo MDS and AML PTPN11 mutations seem to cluster in cases with monosomy 7, [63] [64] [65] and in one study three of four patients with PTPN11 mutations had rearrangement of the MLL gene 64, 66 likewise supporting a cooperation between the two types of mutation in leukemogenesis.
Many other so far unknown genes possibly cooperate in leukemogenesis. Mutations of p53 could represent a third class of mutation as they in our study occurred unrelated to all class I and class II mutations ( Figure 2 ) for instance mutations of AML1 (w 2 ¼ 0.007, P ¼ 0.93).
Genetic abnormalities underlying 7qÀ/À7
As both types of class II mutation of AML1, the chimeric rearrangements and the point mutations, are significantly associated with 7qÀ/À7, in our series 23/32 patients with AML1 mutations presented 7qÀ/À7 compared to only 40/108 without AML1 mutations (P ¼ 0.0006), Fischer's exact test, two sided), we speculate whether the unknown critical genetic event underlying 7qÀ/À7 in some way could interfere with signal transduction and thereby be equivalent with a class I activating mutation. An analysis of the small subgroups of five patients with AML1 point mutations and four patients with chimeric rearrangement of AML1 but normal chromosomes 7 is of interest in this context. Thus, three of the five cases with AML1 point mutations had RAS mutations, and two of the four cases with AML1 chimeric rearranged had a FLT3 or a PTPN mutation, perhaps ''substituting'' the cytogenetic defects 7qÀ/À7. Further studies are required to verify this hypothesis.
Mutually exclusive genetic abnormalities
The biological importance of class I and II mutations and their cooperation in the development of t-MDS and t-AML is supported not only by their many associations to cytogenetic and clinical parameters, but also by a rather high degree of mutual exclusiveness within each class of mutation. For instance, eleven patients with FLT3 mutations did not show mutations of RAS, BRAF, c-Kit or PTPN11. Likewise, none of the 23 patients with balanced chromosome aberrations presented more than one such abnormality. Furthermore, point mutations of AML1 were not observed in the 23 cases with balanced chromosome aberrations.
Only one of our 33 patients with class I mutations had two completely different class I mutations simultaneously, as case 66 presented a mutation of KRAS in addition to a mutation of BRAF.
Our study, however, suggests that the two mutations might be present in different subclones and thereby could have developed independently.
14 Such cases seem to be rather rare. Also in de novo AML, FLT3 and RAS mutations have been observed as negatively associated, 29, 67 and cases with more than one recurrent balanced chromosome aberration are infrequent.
Genetic abnormalities related to progression from t-MDS to t-AML Previously, progression from de novo MDS to AML has mainly been related to the degree of cytopenia, to the percentage of myeloblasts in the bone marrow and to the complexity of the karyotype. 4 Recent studies of t-MDS and t-AML have in addition disclosed point mutations of AML1 and of RAS as significantly associated with leukemic transformation 13, 14 (P ¼ 0.0001 and 0.008 respectively, Fisher's exact test, two sided). The fact that five of 14 patients with RAS mutations also had an AML1 mutation further supports a cooperation between the two abnormalities in leukemogenesis.
Significance of the genetic pathways of t-MDS and t-AML for de novo MDS and de novo AML As the cytogenetic and the genetic abnormalities of de novo MDS and AML are almost identical with those of t-MDS and t-AML, it is reasonable in a discussion of etiology, genetic pathways, leukemic transformation from MDS to AML and antileukemic therapy to extrapolate from one type of disease to the other. In most cases of de novo MDS and AML little is known about the etiology. However, according to the model of genetic pathways in t-MDS and t-AML, etiologic factors of at least three different types must be considered. Alkylating type of damage (pathways I and II), illegitimate gene recombinations related to topoisomerase II (pathways III-VI) and other events of a third, so far unknown type (pathways VII and VIII).
As far as transformation from MDS to AML is concerned, therapy related disease has been shown to offer a specific advantage for such studies, as demonstrated by the significant associations to mutations of AML1 and of RAS.
Regarding therapy, this important issue is best investigated in patients with de novo MDS an AML. Patients with t-MDS or t-AML are often older, have a poor performance status and suffer from various degrees of chronic toxicity. In many cases their primary tumor is not in remission and may even progress during the development of t-MDS or t-AML. Differences from study to study in selection of patients with t-MDS and t-AML for intensive antileukemic therapy may explain the varying, sometimes rather favourable, sometimes very poor results of therapy.
Conclusions
Identification of new genetic abnormalities of different classes will surely increase our understanding of the multistep development of MDS and AML in the future with cooperating mutations in alternative genetic pathways. As the cytogenetic and the genetic abnormalities of therapy-related and of de novo MDS and AML qualitatively are almost identical, research may still benefit from combining the experience from the two subsets of the disease. Particularly, as far as etiology and transformation from MDS to AML are concerned, further investigations of t-MDS and t-AML are important.
As the cytogenetic defects 7qÀ/À7 are closely associated with two-types of AML1 mutation, their so far unknown genetic effects could possibly be related to signal transduction and be equivalent with a type I mutation increasing cellular proliferation and survival.
Whether the molecular biology of MDS and AML will remain heterogeneous with alternative genetic pathways as discussed in this review, or whether a more common genetic abnormality present in several or all of the pathways will be detected, like the BCR-ABL rearrangement in chronic myeloid leukemia, remains to be determined.
